Cu II (atsm) [(diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)] was orally administrated to transgenic SOD1 G93A mice. Results: Treatment significantly prolonged lifespan with preservation of motor neurons. Reduced protein oxidation, attenuated astrocyte, and microglial activation also resulted from treatment.
Amyotrophic lateral sclerosis (ALS) is a progressive paralyzing disease characterized by tissue oxidative damage and motor neuron degeneration. This study investigated the in vivo effect of diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)
(
Amyotrophic lateral sclerosis (ALS)
3 is a fatal neurodegenerative disorder characterized by selective loss of cortical, brainstem, and spinal motor neurons leading to paralysis within 2-5 years of diagnosis. Although the majority of ALS cases are sporadic (sALS), ϳ10% of ALS is familial (fALS) in which dominant mutations in superoxide dismutase 1 (SOD1) and TAR DNA-binding protein-43 are the most common cause (1, 2) . Both sALS and fALS affect the same neurons with similar clinical characteristics, implying common disease mechanisms. Because most SOD1 mutants retain normal antioxidant activity and SOD1 knock-out mice do not develop spontaneous ALS-like symptoms, these mutations may lead to a toxic gain of function rather than loss of superoxide scavenging ability (3, 4) . One such mechanism is oxidative or nitrosative stress resulting from aberrant catalysis conferred by SOD1 mutations (5) (6) (7) . In contrast to wild-type enzyme, mutant SOD1 can promote nitration of tyrosine residues on target proteins in the presence of peroxynitrite formed by superoxide and nitric oxide radicals (8) . Both peroxynitrite and 3-nitrotyrosine have been shown to induce apoptosis in cultured motor neu-rons with evidence of protein nitration (9, 10) , whereas increased levels of 3-nitrotyrosine were reported in ALS spinal cord (11) . Transgenic rodents expressing human mutant SOD1, especially the SOD1 G93A model, develop pathology consistent with ALS patients and have been studied widely for pathogenic mechanisms and testing therapeutic strategies in ALS (3, 12, 13) . Of particular relevance is the finding that nitrated proteins accumulate in spinal cords of mice months before symptom onset (14, 15) , implicating a causal role of nitrosative stress in motor neuron degeneration.
Diacetylbis(N(4)-methylthiosemicarbazonato)copper(II) (Cu II -(atsm)) (see Fig. 1A ) is a neutral, lipophilic, thermodynamically stable complex that is membrane-permeable and readily crosses the blood-brain barrier (16, 17) . Cu II (atsm) prepared with radioactive 64 Cu is currently undergoing clinical trials as a positron emission tomography tracer for hypoxia imaging (18, 19) . It was reported that Cu II (atsm) possesses a SOD1-like antioxidant activity as Cu II (atsm) treatment in a model of ischemic reperfusion injury lowered lipid peroxidation, suggesting that its protective effects were linked to amelioration of radical-mediated tissue damage (16, 20) .
Here, we uncover that Cu II (atsm) is an effective scavenger of peroxynitrite. In the present study, we used a well characterized mouse model with low expression of mutant SOD1 G93A (21, 22) to test the therapeutic effects of Cu II (atsm) on symptom onset and progression of disease. Treatment significantly enhanced animal survival, correlating with reduced neurodegeneration, gliosis, and peroxynitrite-induced oxidative stress in the spinal cords of mice. In addition, we also identified prominent TDP-43 pathology in this model, which is not present in mice with high expression of mutant SOD1 transgenes (23, 24) . Cu II -(atsm) also inhibited the phosphorylation and fragmentation of TDP-43. Overall, the beneficial therapeutic effect of Cu II (atsm) may be due to its ability to inhibit peroxynitrite activity.
EXPERIMENTAL PROCEDURES
Chemical Synthesis-Cu II (atsm) was prepared according to published procedures (25, 26) .
SOD Activity Assay-SOD1 activity was measured using pyrogallol oxidation, as described previously (27) . Briefly, pyrogallol (Sigma-Aldrich) was made up to 0.2 mM in 50 mM TrisHCl (pH 8.2) containing 1 mM diethylenetriaminepentaacetic acid. 10 units/ml SOD1 (isolated from human erythrocytes; Sigma-Aldrich) was preincubated with 1 M Cu II (atsm) made up in acetonitrile. SOD was then nitrated by 1 mM of ONOO Ϫ . SOD activity was measured as the ability to inhibit the oxidation of pyrogallol as determined by increased absorbance at 420 nm after a 1-h incubation.
Transgenic SOD1 G93A Mice-All animal protocols conformed to the Australian National Health and Medical Research Council published code of practice for animal research and conduct. Experimental procedures carried out with mice were approved by the Animal Ethics Committee of The University of Melbourne. Transgenic SOD1 G93A low copy mice used in this study were originally derived from the TgN-[SOD1-G93A]1Gur line from The Jackson Laboratory (Bar Harbor, ME) and develop a delayed phenotype due to a stable reduction in transgene copy number (28) . Hemizygous carriers were backcrossed to C57BL6/J for Ͼ15 generations to produce a congenic line (21 Treatment of mice of 200 days old (defined as symptom onset with body weight loss prior to motor impairment (22) ) was performed daily. Biochemical and histological studies were not carried out for these mice. In both studies, no gender effects were observed with and between treatment groups. Therefore, sexes were combined for analyses. Quantitative real-time PCR assessment confirmed equivalent mutant SOD1 transgene copies in experimental and control mice (14 copies, data not shown).
Motor Performance Test (Rotarod and Stride Length Tests)-The rotarod apparatus was used to monitor disease progression and motor function deficit in mice by recording the latency to fall from a rotating rod (Rota MK2, Monash Uni) within 180 s at a constant speed of 16 rpm as described before (29) . Data are presented as mean Ϯ S.E.
Stride length was assessed by the footprint test using an ϳ60-cm runway strip. An average of six steps per mouse was used per calculation. Both rotarod and stride tests were performed every fortnight beginning at 140 days of age followed by weekly testing at 200 days of age and subsequently twice per week from 240 days onwards. Body weight was recorded weekly from 140 days of age and then twice per week from symptomatic stage (200 days).
Clinical Assessments-Symptom onset was defined as age following first decline from peak body weight. Disease onset was defined either by age of decreased stride length or by rotarod activity from peak performance. Disease progression was confirmed by the presence of hindlimb resting tremor and increased hyporeflexia followed by unilateral or bilateral paralysis. End stage was defined by our ethical requirements as 15-20% body weight loss and Ͻ8 s of rotarod performance.
Mouse Tissue Collection-Mice were euthanized with carbon dioxide and transcardially perfused with butylated hydroxytoluene (Sigma-Aldrich) and phosphatase and protease inhibitor mixtures (Sigma-Aldrich) in PBS. Spinal cord tissues were removed and frozen with dry ice before storing in Ϫ80°C for subsequent biochemical analysis.
Motor Neuron Assessment-Mice killed at 200 days were perfused with 4% paraformaldehyde in PBS, and lumbar spinal cords were dissected out. For mice killed at 230 days, lumbar spinal cords were dissected out and immersion-fixed in 10% neutral buffered formalin. Spinal cords were dehydrated in increasing alcohol concentrations, before embedding in paraffin. For motor neuron counts, 20 serial horizontal sections (6 m thick) per mouse were cut using a microtome as described previously (22) and mounted onto slides. Cresyl violet staining was performed on the 1st, 9th, and 18th serial sections (ϳ50-m interval between each section), and motor neurons in both ventral horns on each section were counted within an area defined by a horizontal line through the central canal.
Spinal Cord Fractionation-Spinal cord fractionation was performed according to published protocols with modification (30) . Briefly, flash-frozen tissue was homogenized gently (7-8 times) using a Dounce homogenizer in 200 l of chilled homogenizing buffer containing 0.25 M sucrose, 5 mM MgCl 2 , 10 mM Tris-HCl, pH 7.4, 1:100 dilution of butylated hydroxytoluene, (0.5 M) and protease inhibitor mixture and phosphatase inhibitor mixture (Sigma-Aldrich). Homogenates were collected, and another 200 l of homogenizing buffer was used to extract residual tissue suspensions. Homogenates were centrifuged at 100 ϫ g for 5 min, and supernatants were centrifuged at 600 ϫ g for 10 min to collect pellets designated as the nuclear fraction. Supernatants were clarified by ultracentrifugation at 80,000 ϫ g for 80 min at 5°C to collect cytoplasmic fractions.
Mouse Pharmacokinetic and Brain Uptake Studies-Cu II -(atsm) was administered orally by gavage at a dose of 30 mg/kg to adult male C57BL/6 or SOD1 G93A mice. At 2 h after dose, mice were anesthetized with sodium pentobarbitone (100 mg/kg, Lethobarb, Jurox, Rutherford, NSW, Australia), and ϳ500 l of blood was withdrawn by terminal cardiac puncture and transferred to heparinized tubes. Blood samples were immediately centrifuged, and duplicate 50-l aliquots of plasma were collected for analysis. Immediately postmortem, brains and spinal cord were removed, blotted to remove residual blood, weighed, and placed into tubes that were snap frozen on dry ice. Plasma and tissue samples were stored frozen at Ϫ80°C until analysis by LC-MS.
Bioanalysis of Plasma and Brain Samples-Quantitation of Cu
II (atsm) in plasma and brain samples was performed using LC-MS (Waters Xevo TQ mass spectrometer coupled to a Waters ACQUITY UPLC). Chromatographic separation was conducted employing a Supelco Ascentis Express RP amide 50 ϫ 2.1-mm column eluting with methanol-water gradient with 0.05% formic acid. Elution of Cu II (atsm) and the internal standard, diazepam, was monitored in positive electrospray ionization multiple-reaction monitoring mode using the transition of 322.0 Ͼ 248.8 and 285.2 Ͼ 154.1, respectively. Whole brains were homogenized in three parts (by weight) of water on ice prior to precipitation. Cu II (atsm) concentrations were quantified in plasma and brain homogenate against calibration standards prepared in blank plasma or brain homogenate, as appropriate. Both samples and standards were prepared by precipitation with acetonitrile followed by centrifugation and analysis of the supernatant. The analytical lower limit of quantitation was 5 ng/ml in mouse plasma and 5 ng/g in mouse brain homogenate.
SOD1 Gel Zymography-SOD1 enzymatic activity was determined according to methods previously described (31) . Briefly, spinal cord cytoplasmic protein fractions from transgenic mice (2 g) and wild-type mice (10 g) were separated using 7.5% native PAGE. Gels were incubated in 2.45 mM nitro blue tetrazolium (Sigma-Aldrich) solution for 20 min and soaked in developer solution (28 mM tetramethylethylenediamine, 28 M riboflavin in 36 mM KH 2 PO 4 ) for 15 min in the dark with constant agitation. Gels were illuminated for 15 min until sufficient contrast between the achromatic zones (dismutation) and blue background was achieved. Gel images were captured using an Epson transmission scanner. SOD1 activities were measured by quantifying absorbance of the clear bands using the Gene Tools analysis software (Syngene, Cambridge, UK).
SDS-PAGE and Western Blotting-Cytoplasmic protein fractions (20 g) were separated using NuPAGE Novex 4 -12% Bis-Tris midi gel electrophoresis (Invitrogen). Proteins were transferred to nitrocellulose membranes, blocked in 0.5% casein in PBS, and incubated for 1 h with the sheep SOD1 (1:1000) (Calbiochem), mouse GFAP (1:20,000) (Dako), rabbit Iba1 (1:1000) (Wako), rabbit TDP-43 (1:1500) (Proteintech), mouse phospho-TDP-43 (1:2000) (Cosmobio), neurofilament (1:1000) (Sigma), or ␤-actin (1:2000) (Sigma) antibodies. HRPconjugated secondary antibodies were used accordingly and incubated for 1 h, and membranes were developed using ECL Advance Lumigen TMA-6 chemiluminescence (GE Healthcare, Rydalmere, Australia). The optical density of target protein bands normalized to actin was quantitated using the GeneGnome chemiluminescence image system (Syngene). Graphs represent analysis of data collected from two midi gels (26 wells) showing data across the whole cohort.
Protein Carbonyl Measurement-Protein oxidation assessed by carbonyl levels in cytoplasmic fractions was measured using the OxyELISA TM oxidized protein quantitation kit (Millipore, S7250) according to the manufacturer's instructions.
3-Nitrotyrosine (3-NT) Enzyme-linked Immunosorbent Assay (ELISA)-3-NT levels were determined by ELISA. Briefly, ELISA was performed at 22°C, and all antibodies were prepared in 0.1% casein in PBS, pH 7.4. Immunosorbent 96-well plates were incubated with cytoplasmic protein fractions (ϳ20 g) diluted in 100 mM carbonate buffer, pH 9.6, for 2 h. After blocking with StabilCoat (Surmodics) for 1 h and washing with PBS containing 0.1% Tween 20, plates were incubated with rabbit anti-tyrosine (1:2000; Cell Signaling Technologies) antibodies for 2 h. Next, plates were incubated with HRP-conjugated secondary antibodies for 1 h and with TMB substrate (GE Healthcare) for 15 min, and the reaction was stopped by the addition of 10% HCl. Absorbance was measured at 450 nm. 3-NT levels were normalized to protein concentration and expressed as the percentage of vehicle-treated wild-type mice.
Immunohistochemistry-Immunostaining procedures were performed as described previously (21) . Antigen retrieval was carried out with citrate buffer for Iba1 only. Sections were quenched with 3% hydrogen peroxide, blocked with the appropriate 20% serum, and incubated with primary antibodies (GFAP 1:500 and Iba1 1:1500) for 1 h. Sections were developed using the universal LSAB ϩ HRP kit (Dako) as described by the manufacturer. Diaminobenzidine tetrahydrochloride reagent (Dako) was applied to sections, before dehydration and mounting with DPX.
Statistical Analysis-Statistical analyses were performed using Kaplan-Meier and log rank tests (Mantel-Cox) for disease onset, duration, and survival (GraphPad Prism version 4 software). Optical density changes between Western and zymography bands were analyzed using SPSS version 17.0. Statistical significance was determined using a Student's t test or one-way analysis of variance with Tukey's honestly significant difference (HSD) test or Dunnett's post hoc analysis and defined as p Ͻ 0.05.
RESULTS
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(atsm) (Fig. 1A) is a neutral, lipophilic, thermodynamically stable complex that was reported to possess SOD1-like antioxidant activity (16, 20) . We have found that Cu II (atsm) has very little SOD1-like activity (supplemental Fig. S1C ), but instead it specifically inhibits the action of peroxynitrite. This is exemplified by the ability of Cu II (atsm) to rescue SOD1 activity in vitro in the presence of peroxynitrite, which inactivates SOD1 (Fig. 1B, supplemental Fig. S1D ). SOD1 activity was measured as the ability to inhibit pyrogallol oxidation. 10 units/ml SOD1 was able to inhibit ϳ80% of pyrogallol oxidation. This SOD1 activity was inhibited by the addition of 1 M peroxynitrite (ONOO Ϫ ) and was rescued by co-treatment with 1 M Cu II (atsm) (p Ͻ 0.01). This is likely due to the ability of Cu II (atsm) to enhance the breakdown of peroxynitrite. ONOO Ϫ inhibited SOD1 activity in a dose-dependent manner and did not interfere with the absorbance of pyrogallol or pyrogallol oxidation. Cu II (atsm) also had no any effect on pyrogallol oxidation (supplemental Fig. S1B) .
To evaluate the potential therapeutic effect of Cu II (atsm) for ALS, the drug was orally administered (30 mg/kg) to presymptomatic SOD1 G93A mice (21, 22) at 140 days. Treatment significantly prolonged mean survival time from 263 Ϯ 3 days (n ϭ 18) to 300 Ϯ 11 days (n ϭ 14, p Ͻ 0.001), a 14% extension in lifespan ( Fig. 2A) . Treatment also significantly delayed the onset of locomotor deficits from 237 Ϯ 2 days to 256 Ϯ 4 days (Fig. 2, B and C, p Ͻ 0.001) and delayed onset of weight loss (182 Ϯ 2 days versus 194 Ϯ 4 days) (Fig. 2D, Table 1 , p Ͻ 0.01). This led to a significant slowing of progression from onset of motor impairment to death by 70% (27 Ϯ 2.4 days versus 45 Ϯ 6.5 days), and weight loss onset to death was extended by 30% (79 Ϯ 4.1 days to 103 Ϯ 7.5 days) ( Table 1) . The dose at 30 mg/kg was well tolerated with no adverse effects observed in WT mice (supplemental Fig. S2 ). The in vivo concentration of Cu II (atsm) 2 h after gavage in WT mice was 304 ng/ml (plasma), 69 ng/g (brain), and 19 ng/g (spinal cord). The concentrations achieved in SOD1 G93A mice were 331 ng/ml (plasma), 67 ng/g (brain), and 15 ng/g (spinal cord) (supplemental Table S2 ).
Next, the more clinically relevant paradigm of postsymptomatic Cu II (atsm) administration was evaluated. Treatment initiated at 200 days (after onset of muscle atrophy according to body weight decline) prolonged lifespan from 250 Ϯ 4 days to 275 Ϯ 3 days (p Ͻ 0.001, Fig. 2E ), a 10% increase in survival. This was accompanied by a significant slowing of motor impairment (p Ͻ 0.05, Table 1 ).
In mice treated presymptomatically, the beneficial effects of Cu II (atsm) were evidenced by significant reduction in several markers of protein oxidative damage in spinal cord. SOD1 G93A mice showed elevated carbonyl levels when compared with wild-type animals, and Cu II (atsm) treatment significantly reduced protein oxidation when compared with vehicle-treated SOD1 G93A mice (p Ͻ 0.001, Fig. 3A) . Furthermore, nitrated protein levels (3-NT) were significantly increased in SOD1 G93A mice when compared with normal animals. Cu II (atsm) treatment markedly reduced 3-NT levels when compared with vehicle-treated SOD1 G93A mice (p Ͻ 0.05, Fig. 3B ), whereas administration to wild-type mice did not affect 3-NT levels. Interestingly, Cu II (atsm) treatment also significantly increased mutant SOD1 enzyme activity in spinal cords of SOD1 G93A mice (ϳ11%, p Ͻ 0.05) (Fig. 3, C and D) . Mutant SOD1 expression levels using a human-specific antibody were unchanged by treatment in SOD1 G93A mice (supplemental Fig. S3 ). Interestingly, Cu II (atsm) treatment also increased endogenous SOD1 activity, although this was not statistically significant.
The beneficial effects of Cu II (atsm) were also demonstrated by significant sparing of lumbar spinal motor neurons in mice. At 200 and 230 days, there was a respective 25% (p Ͻ 0.05) and 21% (p Ͻ 0.01) rescue of motor neurons when compared with vehicle-treated SOD1 G93A mice (Fig. 4, A and B) . Consistent with preservation of motor neurons, neurofilament protein, which was depleted in vehicle-treated SOD1 G93A mice, was also significantly maintained with Cu II (atsm) treatment (p Ͻ 0.001) (Fig. 4, C and D) .
Key cellular and molecular hallmarks of ALS pathology were next examined to investigate the mechanism of Cu II (atsm)-mediated neuroprotection. Immunohistochemical analysis of astrocytic activation (GFAP) revealed widespread gliosis in spinal cords of SOD1 G93A mice when compared with wild-type mice (Fig. 5A) . Cu II (atsm) treatment significantly reduced GFAP-positive cells at 200 and 230 days (Fig. 5A ). This was confirmed by Western analysis of spinal cord lysates where GFAP induction in SOD1 G93A mice was significantly inhibited by Cu II (atsm) (Fig. 5, B and C) . Numbers of Iba1-labeled acti- G93A mice dosed at presymptomatic (Pre-sym) age. Cu II (atsm) extended lifespan of SOD1 G93A mice from 263 Ϯ 3.4 days to 300 Ϯ 10.8 days (mean Ϯ S.E.), p Ͻ 0.001. B and C, motor function assessed by rotarod was significantly improved in drug-treated mice when compared with controls with delayed onset at 256 Ϯ 3.9 days versus 237 Ϯ 1.7, p Ͻ 0.001. D, onset of weight loss determined by age of decline from peak body weight. E, Kaplan-Meier survival curves for Cu II (atsm) treatment started at symptomatic (Sym) age showing a 25-day extension, p Ͻ 0.001. In either study, there were no sex-related differences in survival time. (10) vated microglia were also increased in spinal cords of control SOD1 G93A mice when compared with normal mice (Fig. 5D ), and these numbers were reduced upon Cu II (atsm) treatment (Fig. 5D ). This was in accordance with Western blot analysis showing reduction of Iba1 levels in Cu II (atsm)-treated SOD1 G93A mice to wild-type levels at 230 days (Fig. 5, E and F) . Phosphorylated and truncated TDP-43 species are characteristic of sALS pathology, some forms of mutant SOD1-linked fALS, and low transgene copy number strains of SOD1 G93A mice (32, 33) . In line with these studies, we showed an accumulation of abnormal TDP-43 species in our mouse model at 230 days. Levels of full-length phospho-TDP-43 (pTDP-43) were markedly increased in cytosolic fractions of spinal cord in control SOD1 G93A mice (Fig. 6, A and B) when compared with wild-type animals (p Ͻ 0.01). Cytosolic full-length pTDP-43 species were significantly reduced by Cu II (atsm) treatment (p Ͻ 0.01). C-terminal fragments of pTDP-43 (ϳ25 kDa) also implicated in toxicity (34, 35) were identified in cytosolic fractions of control SOD1
G93A mice, and their production was abolished by Cu II (atsm) in spinal cords (Fig. 6A ).
DISCUSSION
We demonstrate multiple and pronounced therapeutic effects of Cu II (atsm) on clinical and pathological progression in this SOD1
G93A mouse model of ALS. Oral administration of Cu II (atsm) in the presymptomatic phase delayed disease onset and extended survival by 14%, whereas treatment of symptomatic mice still prolonged survival by 10%. Notably, there was a striking slowing of progression from onset of motor deficits to death, increasing the survival interval by 70 and 59% for presymptomatic and symptomatic interventions, respectively. Because muscle atrophy and spinal motor neuron loss are well underway in these mice at symptom onset (22) , our data suggest that Cu II (atsm) is effective even when initiated postsymptomatically, which is clinically relevant. These survival effects were linked to motor neuron rescue, reduced reactive gliosis, and decreased oxidative damage in spinal cords, consistent with effective blood-brain barrier penetration of Cu II (atsm) as demonstrated in this study and others (17) .
The beneficial effect of Cu II (atsm) is likely due to its peroxynitrite scavenging ability, which reduces tissue accumulation of this radical. Peroxynitrite is a powerful oxidant formed by superoxide and nitric oxide; it can nitrate tyrosine or nitrosate cysteine residues and inactivate cellular targets including SOD1, and it has been shown to induce apoptosis in motor neurons and play an important role in ALS (8, 9, 36, 37) . Although SOD1 mutations affect the scavenging of O 2 Ϫ , they also enhance SOD1-mediated peroxynitrite-induced nitration of many proteins (8) . Nitrated products have been found to accumulate in spinal cords of SOD1 G93A mice (14, 15) as confirmed here. Gene deletion of inducible nitric oxide synthase delayed disease onset and significantly extended the lifespan of SOD1 G93A mice (38) , supporting our findings that inhibiting nitrosative stress is protective in this model. We demonstrate that Cu II (atsm) inhibits protein nitration in mice, consistent with diminished peroxynitrite accumulation in vivo. Our in vitro study also showed that peroxynitrite inhibited SOD1 activity, which was prevented by Cu II (atsm) (Fig. 1B) . Our ani- G93A mouse spinal cord. A, protein carbonyl levels were determined using OxyELISA in 230-day-old mice and normalized to protein levels. The data are expressed as the percentage of change over vehicle (Veh)-treated wild-type mice. B, 3-NT levels were determined by ELISA and normalized to protein levels. The data are expressed as the percentage of change over vehicle-treated wild-type mice. 3-NT levels were increased in SOD1 G93A mice when compared with wild types and reduced with Cu II (atsm) treatment. C, SOD1 enzymatic activity gel analysis of spinal cords. An equal amount of protein was loaded for WT (10 g) and SOD1
G93A (2 g) mice, respectively. D, quantitation of SOD1 activity expressed relative to respective vehicle-treated groups. Cu II (atsm) treatment significantly increased SOD1 activity when compared with vehicle-treated transgenic mice. WT, non-transgenic (Non TG) littermate of the SOD1 G93A mice. n is shown at bottom of bars (mean Ϯ S.E.). One-way analysis of variance with Tukey's post hoc test, *, p Ͻ 0.05, **, p Ͻ 0.01, ***, p Ͻ 0.001 difference. ns, not significant. mal data showed that SOD1 activity in spinal cord was enhanced in Cu II (atsm)-treated mice when compared with vehicle-treated mice (Fig. 3C) (42) , and our data showing that Cu II (atsm) extends survival interval even when administered postsymptomatically are consistent with modulation of glial activation and function. Further evidence for this proposal is that induction of astrocyte-derived pro-inflammatory metalloproteinase 9 activity in this model (22) was reduced in treated animals (data not shown). Peroxynitrite is known to stimulate astrocytic activation provoking motor neuron death (9) , suggesting that glial cells are also likely targets for the Cu II (atsm) action and neuroprotection observed. The identification of mislocalized TDP-43 in all sALS cases and mutant TDP-43-linked fALS was a recent breakthrough toward understanding ALS pathogenesis (33, 43) . Pathological TDP-43 species include nuclear TDP-43 mislocalized to the cytosol, a truncation producing ϳ25-kDa C-terminal fragments, ubiquitination, and phosphorylation in affected tissues of patients (33) . Previous studies with SOD1 G93A low copy mice with a lifespan of 224 -281 days reported mislocalization of neuronal TDP-43 by microscopy (32) . This contrasts with mice highly expressing SOD1 G93A where TDP-43 abnormalities were absent (23, 24) or rare (44) . Here, we identify biochemical hallmarks of abnormal TDP-43 such as truncation and phosphorylation in our SOD1 G93A mice with an average lifespan of 250 -270 days (21, 22) . Detection of cytosolic C-terminal pTDP-43 fragments here is also in line with observations in sALS tissues (33, 45, 46) . This indicates that mice with low level accumulation of mutant SOD1 may recapitulate key pathological and biochemical features of TDP-43 proteinopathy as observed in ALS. The late onset and slow disease progression in these mice, unlike the aggressive disease course in other lines (23, 24) , may therefore allow sufficient time for a more relevant disease model to develop as proposed by others (23, 32) . Cu II -(atsm) treatment robustly reduced pathological forms of fulllength as well as C-terminal fragmented pTDP-43, which may contribute to the neuroprotective effects and survival benefits seen. This is the first study showing drug modulation of TDP-43 pathology in vivo. Furthermore, given the mechanism of action of Cu II (atsm), these data suggest a role for oxidative stress in the genesis of pathologic TDP-43. Indeed, recent findings suggest that TDP-43 is recruited to cytoplasmic stress granules under pro-oxidative conditions (47, 48) . We have also recently shown that oxidative stress leads to the accumulation of TDP-43 in stress granules and that this may be a precursor for TDP-43 aggregation (49). Most relevant here was the demonstration that SIN1, a peroxynitrite donor, was able to induce abnormal cellular processing of TDP-43 resulting in its cytoplasmic accumulation (49) . It remains to be determined whether Cu II (atsm) can inhibit peroxynitrite-mediated TDP-43 pathology in these cell models. Although inhibition of peroxynitrite was the driving force behind the rationale to test Cu II (atsm) in the ALS animal model here, our data do not exclude other possible mechanisms. For example, we have demonstrated that kinases can control TDP-43 cytosolic accumulation (49) . However, more definitive evidence of how Cu II -(atsm) modulates aberrant TDP-43 metabolism will require further work. In summary, our findings are that oral administration of the peroxynitrite scavenger Cu II (atsm) reduces oxidative and nitrosative tissue burden, TDP-43 pathology, and motor neuron loss, leading to significant clinical improvement in ALS model mice. This indicates that this class of compound has promise as a therapeutic candidate for ALS and possibly other major forms of neurodegenerative disorders where oxidative and nitrosative stress are the driving force of disease progression.
